Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
SRSF3-TRIM28-MDC1 prevents DNA damage caused by R-loops in fatty liver disease in mice
Panyisha Wu, Manasi Das, Yanting Wang, Yichun Ji, Yuli Wu, Deepak Kumar, Lily J. Jih, Nicholas J.G. Webster
Panyisha Wu, Manasi Das, Yanting Wang, Yichun Ji, Yuli Wu, Deepak Kumar, Lily J. Jih, Nicholas J.G. Webster
View: Text | PDF
Research Article Endocrinology Hepatology

SRSF3-TRIM28-MDC1 prevents DNA damage caused by R-loops in fatty liver disease in mice

  • Text
  • PDF
Abstract

Serine-rich splicing factor 3 (SRSF3) is crucial for the metabolic functions of the liver. The genetic deletion of SRSF3 in mouse hepatocytes impairs hepatic lipid and glucose metabolism and leads to fibrosis and formation of hepatocellular adenoma that progresses to hepatocellular carcinoma. SRSF3 protein is proteosomally degraded in metabolic-dysfunction associated fatty liver disease (MAFLD) and metabolic-dysfunction-associated steatohepatitis (MASH). We show here that depleting SRSF3 protein in hepatocytes promoted R-loop accumulation and increased DNA damage in the liver. Prevention of SRSF3 degradation in vivo protected hepatocytes from DNA double-strand breaks in mice with MASH. This protection extended to other DNA-damaging agents such as camptothecin, palmitic acid, or hydrogen peroxide when tested on HepG2 cells in vitro. SRSF3 interacted with TRIM28 and MDC1, which are components of the ATM DNA-damage repair complex, and knockdown of any of these 3 proteins reduced the expression of the other 2 proteins, suggesting they form a functional complex. Lastly, by preventing degradation of SRSF3, we were able to reduce tumors in a diethyl-nitrosamine–induced (DEN-induced) model of cirrhotic HCC. These findings suggest that maintenance of SRSF3 protein stability is crucial for preventing DNA damage and protecting liver from early metabolic liver disease and progression to HCC.

Authors

Panyisha Wu, Manasi Das, Yanting Wang, Yichun Ji, Yuli Wu, Deepak Kumar, Lily J. Jih, Nicholas J.G. Webster

×

Figure 6

TRIM28 and MDC1 proteins are reduced by lipid overload.

Options: View larger image (or click on image) Download as PowerPoint
TRIM28 and MDC1 proteins are reduced by lipid overload.
(A) Immunoblots ...
(A) Immunoblots for TRIM28, TRIM28(pSer473), and MDC1 in hepatocytes from mice on high-fat diet (MAFLD), Western diet (MASH), or normal chow (control). Actin loading control for TRIM28 is same as in Figure 1A for SRSF3. Graph shows quantification of protein levels normalized to β-actin (n = 3–4/group). Lean mice are shown in white, MAFLD mice in yellow, and MASH mice in red. (B) Immunoblots of TRIM28, TRIM28(pSer473), MDC1, and ATM from HepG2 cells treated with methyl-β-cyclodextrin (MBCD; 1 mM) as control or palmitic acid (500 μM) complexed to MBCD (1 mM) for 12 hours. Graph shows quantification of protein levels normalized to β-actin (n = 3/group). (C) Immunoblots of TRIM28, TRIM28(pSer473), MDC1, and SRSF3 in HepG2 cells infected with AAV8 expressing GFP, SRSF3-WT, SRSF3-K11R (MOI 500,000 for 48 hours) followed by 500 μM PA treatment for 12 hours. Graph shows quantification of protein levels normalized to β-actin (n = 3/group). Control group is shown in white, GFP in green, WT in yellow, and K11R in red. All quantified results are presented as mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by 1-way ANOVA.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts